Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06023004
Other study ID # The Diverticulitis study
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2022
Est. completion date May 2025

Study information

Verified date August 2023
Source University of Aarhus
Contact Claus L Andersen, PhD
Phone +45 7845 5319
Email cla@clin.au.dk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Acute colonic diverticulitis is when a part of the colon gets swollen and inflamed. The diagnosis is based on a CT scan, which can show thickening of the colonic walls and infiltration of the diverticula. These changes and the concomitant symptoms can overlap with colorectal cancer (CRC). Therefore, the guidelines suggest that people with diverticulitis should be offered a colonoscopy to ensure, that CRC is not the underlying cause of the changes and symptoms. In Denmark, a lot of people get hospitalized each year due to diverticulitis, and many of them end up having colonoscopies with the purpose of excluding CRC. Currently, there are no methods for guiding colonoscopies following a diverticulitis episode, resulting in numerous unnecessary colonoscopies each year. In the Diverticulitis study, we want to investigate if a simple blood test analyzed for the presence of circulating tumor DNA (ctDNA), can help us decide who needs a colonoscopy. We will collect blood samples from 220 people with diverticulitis and categorize them into ctDNA positive and negative groups. The ctDNA category will be compared to the colonoscopy results to see if there is a correlation between being ctDNA positive and having a CRC diagnosed at the colonoscopy. This study could change clinical practice since we anticipate that ctDNA-guided triaging of diverticulitis patients is a cost-effective strategy for selecting diverticulitis patients needing colonoscopy, ensuring detection of the underlying CRC, and significantly reducing the number of patients undergoing unnecessary colonoscopy.


Description:

KEY POINTS - Colonoscopy is recommended after acute diverticulitis to rule out CRC, and yearly more than 2000 colonoscopies are performed. - CRC incidence is low in the diverticulitis population and most colonoscopies are unnecessary. It takes approximately 100-200 colonoscopies to diagnose just 1 CRC. - ctDNA is a minimally invasive and extraordinarily powerful biomarker of cancer. GOALS ● To use ctDNA analysis to triage diverticulitis patients for colonoscopy. Diagnosing the same CRCs, but minimizing the number of patients needing colonoscopy PERSPECTIVES - Practice-changing evidence for ctDNA-guided triaging of diverticulitis patients for colonoscopy, an important and well-recognized clinical dilemma in the management of CRC. - Evaluation of the cost-effectiveness of ctDNA-guided triaging versus standard-of-care. PROJECT DESCRIPTION For patients who have experienced an episode of acute colonic diverticulitis, Danish and international guidelines recommend opportunistic screening with colonoscopy to rule out CRC as the underlying reason for the diverticulitis symptoms. In Denmark, there are more than 4000 hospitalizations per year due to diverticulitis. Accordingly, a substantial number of post-diverticulitis colonoscopies are performed each year to rule out underlying CRC. Colonoscopy is an invasive procedure associated with discomfort and pain in more than 50% of patients. The procedure also carries the risk of complications such as perforation and hemorrhage, particularly for patients with diseased intestines such as diverticulitis patients. CRC prevalence in suspected diverticulitis patients is low, <2% overall, and as low as 0.5% for uncomplicated diverticulitis. Thus, an unreasonably high number of colonoscopies, ranging from 50 and up to more than 200, are needed to diagnose 1 CRC. In comparison, a >4% CRC prevalence is considered the minimal acceptable among patients selected for follow-up colonoscopy in the Danish nationwide CRC screening program, corresponding to less than 25 colonoscopies per CRC. Hence, it may be questioned whether the current guidelines on follow-up colonoscopy after diverticulitis are at all acceptable, both from a patient perspective and from a health-economy perspective. However, it has been very difficult to change. Consequently, there is an urgent need for a highly sensitive, low-risk, minimally invasive cancer detection test that can be used to triage newly diagnosed diverticulitis patients and ensure that underlying CRC is still diagnosed while minimizing the number of patients needing colonoscopy. Here, we propose to conduct a case/control study to explore the feasibility of using our recently developed TriMeth ctDNA analysis test for this purpose. We hypothesize that ctDNA analysis can triage diverticulitis patients for colonoscopy and achieve a diagnosis of prevalent CRC but at a substantially lower colonoscopy/CRC ratio. For this purpose, we will use our tumor-agnostic ctDNA analysis "TriMeth". TriMeth was originally developed as a CRC screening tool for selecting individuals from the average-risk population for colonoscopy. Accordingly, the threshold for calling the test positive was set with the objective of high specificity. At 99% specificity, it has a sensitivity of 85%. Based on data from the original development and validation cohorts (400 CRC and 800 controls), we will tailor TriMeth for this specific purpose, i.e., setting the threshold for test positivity to achieve near 100% sensitivity by accepting a lower specificity. Second, we will conduct a case-control study to validate this new TriMeth-diverticulitis threshold in the target population. We expect a minimum of 20 cases with CRC diagnosed at colonoscopy after suspected diverticulitis to be identified through the IMPROVE study (NCT03637686). For each case, 10 controls will be randomly selected (to a minimum of 200 total) from patients with CT-verified diverticulitis and a follow-up colonoscopy without CRC. Diverticulitis patients may at the time of colonoscopy exhibit symptoms, that would in any case serve as an absolute indication for colonoscopy (patients age >40 with changes in bowel habits >1 month, rectal bleeding, iron-deficiency anemia, or excessive weight-loss). Therefore, in addition to blood sampling, we will at the time of CRC diagnosis or negative colonoscopy collect information on other established indicators for colonoscopy. As part of the study, we will conduct a health-economy assessment comparing the TriMeth-guided approach to the current practice of "colonoscopy for all". The primary outcome is the sensitivity and specificity of TriMeth for CRC detection in this population. The secondary outcome is health economy, considering the other indicators for colonoscopy. If high sensitivity and clinically and economically relevant colonoscopy-sparing potential is demonstrated, the data will be presented to the Danish Colorectal Cancer Group and the Danish Health Technology Council with the aim of obtaining approval to change the national guideline and implement the approach.


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date May 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - CT-verified diverticulitis eligible for a follow-up colonoscopy Exclusion Criteria: - Unable to provide oral and written informed consent - Recent colonic imaging and no need for renewed visualization of the colonic mucosa deemed by the attending doctor

Study Design


Locations

Country Name City State
Denmark Herlev Hospital Herlev Capital Region Of Denmark
Denmark Regional Hospital Horsens Horsens Central Denmark Region
Denmark Odense University Hospital Odense The Region Of Southern Denmark
Denmark Regional Hospital Randers Randers Central Denmark Region
Denmark Regional Hospital Viborg Viborg Central Denmark Region

Sponsors (5)

Lead Sponsor Collaborator
University of Aarhus Aarhus University Hospital, Odense University Hospital, Regional Hospital Horsens, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

References & Publications (5)

Andersen JC, Bundgaard L, Elbrond H, Laurberg S, Walker LR, Stovring J; Danish Surgical Society. Danish national guidelines for treatment of diverticular disease. Dan Med J. 2012 May;59(5):C4453. — View Citation

Jensen SO, Ogaard N, Nielsen HJ, Bramsen JB, Andersen CL. Enhanced Performance of DNA Methylation Markers by Simultaneous Measurement of Sense and Antisense DNA Strands after Cytosine Conversion. Clin Chem. 2020 Jul 1;66(7):925-933. doi: 10.1093/clinchem/hvaa100. — View Citation

Jensen SO, Ogaard N, Orntoft MW, Rasmussen MH, Bramsen JB, Kristensen H, Mouritzen P, Madsen MR, Madsen AH, Sunesen KG, Iversen LH, Laurberg S, Christensen IJ, Nielsen HJ, Andersen CL. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and validation study. Clin Epigenetics. 2019 Nov 14;11(1):158. doi: 10.1186/s13148-019-0757-3. — View Citation

Meyer J, Orci LA, Combescure C, Balaphas A, Morel P, Buchs NC, Ris F. Risk of Colorectal Cancer in Patients With Acute Diverticulitis: A Systematic Review and Meta-analysis of Observational Studies. Clin Gastroenterol Hepatol. 2019 Jul;17(8):1448-1456.e17. doi: 10.1016/j.cgh.2018.07.031. Epub 2018 Jul 26. — View Citation

Ogaard N, Reinert T, Henriksen TV, Frydendahl A, Aagaard E, Orntoft MW, Larsen MO, Knudsen AR, Mortensen FV, Andersen CL. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. Eur J Cancer. 2022 Mar;163:163-176. doi: 10.1016/j.ejca.2021.12.026. Epub 2022 Jan 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary ctDNA analysis Blood samples will be categorized as either ctDNA positive or negative After recruitment of the last patient, we expect that ctDNA analyses can be performed within 6 months
Secondary Cost-effectiveness of treatment Assessment of the cost-effectiveness of "ctDNA guided" versus "opportunistic" colonoscopy screening of the diverticulitis patients After recruitment of the last patient, we expect that cost-effectiveness analyses can be performed within 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A